Fundraising FoxLengo Therapeutics
Menlo Park, US · Founded 2019 · Delaware corporation · 1 known investors
Find your way into Lengo Therapeutics
Sign up to see every warm intro you have to Lengo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lengo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Frazier-founded precision oncology company developing CNS-penetrant inhibitors; acquired by Blueprint Medicines in 2021.
Founders & leadership
HJ
Helen JenkinsChief Executive Officer
SB
DJ
David JohnsonExecutive
JS
JIA SHENG LOOExecutive
Board
DE
Daniel Estes, Ph.D.President
RU
Roger Ulrich, Ph.D.Board director
AC
TS
Tracy Saxton, Ph.D.Board director
Investors · 1
Reported raises · per SEC filings
Form D private placements$17.7M disclosed across 1 of 2 rounds · 2020–2023
▶$7MofferedApr 2023 · Other TechnologyRule 506(c)
▶$7MofferedApr 2023 · Other Technology
Rule 506(c)Officers, directors & promoters on the filing
- JIA SHENG LOOExecutive Officer, Director, Promoter
- Offering amount
- $7M
- Placement agents
- JIA SHENG LOO
- Incorporated
- Corporation, New York, 2023
- Federal exemptions
- 06c
▶$17.7MraisedApr 2021 · 4 investors · PharmaceuticalsRule 506(b)
▶$17.7MraisedApr 2021 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daniel Estes, Ph.D.Executive Officer, Director
- Tracy Saxton, Ph.D.Director
- Helen JenkinsExecutive Officer, Director
- Roger Ulrich, Ph.D.Director
- Steve BaileyExecutive Officer
- Anna ChenExecutive Officer
- David JohnsonDirector
- Offering amount
- $17.7M
- Amount sold
- $17.7M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Lengo Therapeutics do?
- Frazier-founded precision oncology company developing CNS-penetrant inhibitors; acquired by Blueprint Medicines in 2021.
- Who are Lengo Therapeutics's investors?
- Lengo Therapeutics's investors include Frazier Life Sciences.
- How much funding has Lengo Therapeutics raised?
- Lengo Therapeutics has disclosed $17.7M raised across 1 of its 2 known rounds.
- Where is Lengo Therapeutics headquartered?
- Lengo Therapeutics is headquartered in Menlo Park, US.